Clinical trials
Participation clinical trials
Below are recruiting participation clinical trials, each written for real people, not researchers. We’re tracking 2,283 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07104565RecruitingPhase 2
Tafasitamab for autoimmune blood cell disorders
This study tests a new drug, tafasitamab, for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that has not been controlled well by other treatments. The goal is to see if it is safe and can help manage these blood cell disorders.
Glendale, ArizonaAges 18 years+ - NCT07099547RecruitingPhase 2
ZG005 plus chemo for advanced gallbladder cancer
This trial tests a new drug called ZG005 combined with standard chemotherapy for people with advanced gallbladder cancer. The goal is to see if adding ZG005 helps shrink tumors or slow the disease.
Hefei, AnhuiAges 18–75 - NCT07105709RecruitingPhase 2
Extension study for early Alzheimer's treatment
This study is a follow-up for people who completed a previous trial of an experimental treatment for early Alzheimer's disease. It will continue to test the treatment's safety and effects over a longer period.
Maitland, FloridaAges 50–85 - NCT07099898RecruitingPhase 3
Study of a new drug for relapsed small cell lung cancer
This study tests a new drug (GSK5764227) for people whose extensive-stage small cell lung cancer has gotten worse after platinum chemotherapy combined with immunotherapy. The goal is to see if this targeted treatment can help shrink tumors and control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07098988RecruitingPhase 2
Visugromab plus standard chemo-immunotherapy for lung cancer
This trial tests an experimental drug called visugromab added to standard chemotherapy and immunotherapy for people newly diagnosed with advanced non-squamous lung cancer. It aims to see if the combination works better than standard treatment alone.
Birmingham, AlabamaAges 18 years+ - NCT07096674RecruitingPhase 2
Long-term study of ORX750 for narcolepsy and idiopathic hypersomnia
This trial is for people who have already completed the main CRYSTAL-1 study of ORX750. It tests the long-term safety and effects of the drug, so you can continue treatment if it was helping you.
Auburn, AlabamaAges 18–65 - NCT07100119RecruitingPhase 1
Study of LY4256984 for people with sporadic ALS
This trial tests a new medicine called LY4256984 for people with sporadic ALS (ALS not caused by a known genetic mutation). The goal is to see if the drug is safe and how it affects the body. It may offer a new treatment option for people recently diagnosed with ALS.
LeuvenAges 18–75 - NCT07098663RecruitingPhase 2
Study of MKP10241 for weight loss and diabetes control
This study tests an investigational drug called MKP10241 in healthy people, people with obesity, and people with type 2 diabetes. It aims to see how the drug affects blood sugar, weight, and overall safety. It may be an option if you have obesity or type 2 diabetes managed by diet and/or metformin.
Bayswater, VictoriaAges 18–60 - NCT07098091Enrolling by invitationPhase 1
Testing the safety of YD0293 in healthy adults
This phase 1 study tests a new medicine called YD0293 in healthy volunteers to see if it is safe and how the body handles it. It helps find the right dose for future studies.
Suzhou, JiangsuAges 18–45 - NCT07105111RecruitingPhase 4
Valbenazine for tardive dyskinesia after other treatment
This study tests if valbenazine helps adults with tardive dyskinesia whose symptoms continue even after taking or stopping another similar medication. Tardive dyskinesia involves uncontrollable movements from long-term use of certain mental health drugs.
Bryant, ArkansasAges 18 years+ - NCT07102381RecruitingPhase 2
Zanidatamab plus chemo before surgery for HER2+ breast cancer
This trial tests a new drug called zanidatamab combined with chemotherapy to shrink HER2-positive breast cancer before surgery. It may help improve treatment outcomes for people with stage 2 or 3 breast cancer that has not spread.
Long Beach, CaliforniaAges 18 years+ - NCT07101328RecruitingPhase 1
Study of LY4152199 for Lymphoma That Returned or Didn't Respond
This study tests a new medicine called LY4152199 for people with certain types of lymphoma (follicular or diffuse large B-cell) that came back or didn't respond to previous treatment. The goal is to see if the drug is safe and how well it works.
Duarte, CaliforniaAges 18 years+ - NCT07100106RecruitingPhase 1/Phase 2
Study of GDC-4198 alone or with giredestrant for advanced breast cancer
This trial tests a new treatment (GDC-4198) alone or with another drug (giredestrant) compared to a standard combination (abemaciclib and giredestrant) for people with advanced hormone receptor-positive, HER2-negative breast cancer that has progressed after previous treatments.
Huntsville, AlabamaAges 18 years+ - NCT07094113RecruitingPhase 1
AMG 410 alone or with other drugs for KRAS-altered advanced cancers
This study tests a new drug called AMG 410 by itself or with other medicines in people whose cancer has a specific change in the KRAS gene. It is for advanced or metastatic solid tumors that have not responded to standard treatments or who have chosen not to take them.
Duarte, CaliforniaAges 18 years+ - NCT07089875RecruitingPhase 3
Testing dotinurad vs allopurinol for people with gout
This study compares a new gout medicine called dotinurad to the common medicine allopurinol. It is for people who have had gout for at least a year, have had at least 2 gout attacks in the last year, and are already taking a stable dose of allopurinol but still have high uric acid levels.
Birmingham, AlabamaAges 18–75 - NCT07090785RecruitingPhase 1
Healthy volunteer study of LY4088044
This trial tests a new medicine called LY4088044 in healthy people to see how it affects the body. It helps doctors learn about the drug's safety before testing it in patients with a disease.
Los Alamitos, CaliforniaAges 18–65 - NCT07086976RecruitingPhase 3
Study of oral rilzabrutinib for warm autoimmune hemolytic anemia
This trial tests an oral medication (rilzabrutinib) against a placebo for people with warm autoimmune hemolytic anemia (wAIHA). It aims to see if the drug can help control the disease with fewer side effects than current treatments.
Phoenix, ArizonaAges 18 years+ - NCT07090161RecruitingPhase 2
Study of iloperidone for uncontrolled high blood pressure
This trial tests if iloperidone can lower blood pressure in people whose high blood pressure is not controlled by current medications. You may qualify if your blood pressure is still high after weeks of treatment.
Phoenix, ArizonaAges 18–65 - NCT07095127RecruitingPhase 2
Testing NVG-2089 for immune thrombocytopenia
This trial tests an investigational drug called NVG-2089 for adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. The goal is to see if it safely raises platelet counts and improves bleeding symptoms.
Washington D.C., District of ColumbiaAges 18–80 - NCT07088926RecruitingPhase 2
Study of a new drug for bronchiectasis with chronic pseudomonas infection
This study tests an investigational drug given through an IV to see if it can reduce lung infections and flare-ups in people with bronchiectasis who have a chronic pseudomonas infection. Participation may help improve symptoms and quality of life.
Orange, CaliforniaAges 12 years+ - NCT07093333RecruitingPhase 2
Testing a new antibody treatment for anti-NMDAR brain disease
This study tests a new medicine (ART5803) in people whose immune system attacks a brain receptor called NMDAR, causing encephalitis (brain swelling) or psychiatric symptoms. It aims to see if the medicine can reduce symptoms like confusion, memory problems, or psychosis.
SeoulAges 18–65 - NCT07095452RecruitingPhase 2/Phase 3
Newly diagnosed myeloma: comparing drug combinations for non-transplant patients
This trial tests a new combination of two drugs (etentamig and daratumumab) against the current standard of daratumumab plus lenalidomide and dexamethasone in people recently diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see which combination better controls the disease while keeping side effects manageable.
Scottsdale, ArizonaAges 18 years+ - NCT07088068RecruitingPhase 3
Teplizumab for newly diagnosed type 1 diabetes
This study tests whether teplizumab can help keep the body making insulin in people recently diagnosed with type 1 diabetes. It is for children and young adults aged 1 to 25, and compares the drug against a placebo.
Scottsdale, ArizonaAges 1–25 - NCT07086105RecruitingPhase 1
Study of Adze1.C for advanced melanoma
This trial tests a new injected virus therapy (Adze1.C) for people with advanced melanoma that hasn't responded to other treatments. The virus is designed to attack tumors directly and may help your immune system fight the cancer.
Southport, QueenslandAges 18 years+
Hear when a new Participation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participation?
- Yes. Clin2 currently lists 2,283 recruiting participation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.